![conference banner](/images/conference-banner.jpeg)
Abstract
Glucocorticoids (GCs) constitute the most important and widely prescribed class of anti-inflammatory and immunosuppressive drugs. Since their first clinical use more than half a century ago, they have been employed for therapeutic treatment in a variety of diseases such as atopic disorders, autoimmune diseases and cancer. Their efficacy is related to their capability to reduce the expression and activity of many pro-inflammatory agents, that is named “transrepression”. Unfortunately, they also induce serious adverse effects, in particular upon high dosage and prolonged usage, many of which are due to the transcription of genes involved in metabolic processes, that is called “transactivation”. This discrepancy is the driving force for discovery of novel safer GC receptor ligands, such as selective GCs receptor agonists (SEGRAs) able to induce transrepression, whilst avoiding transactivation. The aim of this review is to give an overview of the above-mentioned mechanisms at the basis of GCs action and to summarize the results obtained with SEGRAs in terms of efficacy versus side effects and discuss the opportunities and challenges that this class of ligands might offer for clinical arena.
Keywords: Glucocorticoids, transactivation, transrepression, selective glucocorticoid receptor agonists, immunosuppressive drugs, atopic disorders, autoimmune diseases, cancer, pro-inflammatory agents, transcription, GC receptor ligands, SEGRAs, steroid, Hodgkin's lymphoma, corticosteroids, hydrocortisone, cortisol, prednisolone, methylprednisolone, mineralcorticoid, fluorinated dexamethasone, betamethasone compounds, rheumatic diseases, immune system, osteoporosis, skin atrophy, cushingoid appearance, glaucoma, immunosuppression, GCs effects, osteoblasts, osteocytes, hypothalamic neurons, corticotrophin releasing factor, pituitary corticotroph, hypothalamus-pituitary-adrenal-axis, hyperplasia, DNA-binding domain, ligand-binding domain, zinc-finger motifs, glucocorticoid response element, mitogen-activated protein kinase, hydroxysteroid dehydrogenase, SRC-1, DNA sequences, Cytosolic GR, Immunostimulation, TCR signaling, lymphocyte-specific kinase, glutaminsynthetase, ZK-216348, adrenocorticotropic hormone, osteoprotegerin, PF-4171327, PF-251802
Current Pharmaceutical Design
Title: Glucocorticoids Pharmacology: Past, Present and Future
Volume: 16 Issue: 32
Author(s): Stefania Gessi, Stefania Merighi and Pier Andrea Borea
Affiliation:
Keywords: Glucocorticoids, transactivation, transrepression, selective glucocorticoid receptor agonists, immunosuppressive drugs, atopic disorders, autoimmune diseases, cancer, pro-inflammatory agents, transcription, GC receptor ligands, SEGRAs, steroid, Hodgkin's lymphoma, corticosteroids, hydrocortisone, cortisol, prednisolone, methylprednisolone, mineralcorticoid, fluorinated dexamethasone, betamethasone compounds, rheumatic diseases, immune system, osteoporosis, skin atrophy, cushingoid appearance, glaucoma, immunosuppression, GCs effects, osteoblasts, osteocytes, hypothalamic neurons, corticotrophin releasing factor, pituitary corticotroph, hypothalamus-pituitary-adrenal-axis, hyperplasia, DNA-binding domain, ligand-binding domain, zinc-finger motifs, glucocorticoid response element, mitogen-activated protein kinase, hydroxysteroid dehydrogenase, SRC-1, DNA sequences, Cytosolic GR, Immunostimulation, TCR signaling, lymphocyte-specific kinase, glutaminsynthetase, ZK-216348, adrenocorticotropic hormone, osteoprotegerin, PF-4171327, PF-251802
Abstract: Glucocorticoids (GCs) constitute the most important and widely prescribed class of anti-inflammatory and immunosuppressive drugs. Since their first clinical use more than half a century ago, they have been employed for therapeutic treatment in a variety of diseases such as atopic disorders, autoimmune diseases and cancer. Their efficacy is related to their capability to reduce the expression and activity of many pro-inflammatory agents, that is named “transrepression”. Unfortunately, they also induce serious adverse effects, in particular upon high dosage and prolonged usage, many of which are due to the transcription of genes involved in metabolic processes, that is called “transactivation”. This discrepancy is the driving force for discovery of novel safer GC receptor ligands, such as selective GCs receptor agonists (SEGRAs) able to induce transrepression, whilst avoiding transactivation. The aim of this review is to give an overview of the above-mentioned mechanisms at the basis of GCs action and to summarize the results obtained with SEGRAs in terms of efficacy versus side effects and discuss the opportunities and challenges that this class of ligands might offer for clinical arena.
Export Options
About this article
Cite this article as:
Gessi Stefania, Merighi Stefania and Andrea Borea Pier, Glucocorticoids Pharmacology: Past, Present and Future, Current Pharmaceutical Design 2010; 16 (32) . https://dx.doi.org/10.2174/138161210793797915
DOI https://dx.doi.org/10.2174/138161210793797915 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Interleukin-1β for Pain
CNS & Neurological Disorders - Drug Targets Cyclosporin and Organ Specific Toxicity: Clinical Aspects, Pharmacogenetics and Perspectives
Current Clinical Pharmacology Desirability Based Optimization of New Mesalazine Modified Release Formulations: Compression Coated Tablets and Mini Tablets in Capsules
Letters in Drug Design & Discovery Mouse Models of Autoimmune Diseases: Immune Thrombocytopenia
Current Pharmaceutical Design Systemic Lupus Erythematosus and Other Autoimmune Diseases from Endogenous and Exogenous Agents: Unifying Theme of Oxidative Stress
Mini-Reviews in Medicinal Chemistry CCR1 Chemokine Receptor Antagonist
Current Pharmaceutical Design Needle-free Gene Delivery Through the Skin: An Overview of Recent Strategies
Current Pharmaceutical Design Mechanisms of Altered Cell Immunity and Cytotoxicity in COPD
Current Drug Targets Natural Products to Improve Quality of Life Targeting for Colon Drug Delivery
Current Drug Delivery PROGRAMMED Cell Clearance: Molecular Mechanisms and Role in Autoimmune Disease, Chronic Inflammation, and Anti-Cancer Immune Responses
Current Immunology Reviews (Discontinued) An Update on Autoinflammatory Diseases
Current Medicinal Chemistry Control of Autoimmune Diseases by the B7-CD28 Family Molecules
Current Pharmaceutical Design No Zinc Deficiency But a Putative Immunosuppressive Role for Labile Zn in Patients with Systemic Autoimmune Disease
Current Rheumatology Reviews Comparative Molecular Characterization to Reveal Surface Behaviour of Non-proteolytic Bromelain Mutants
Current Pharmaceutical Biotechnology Inhibition of Type 1 Diabetes Development by Vitamin D Receptor Agonists
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Anti-CD20 in Targeting B Lymphocytes for the Treatment of Autoimmune Diseases: Clinical Benefits and Insights into the Role of B Lymphocytes in Pathophysiology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Critical Role of Toll-Like Receptor Signaling Pathways in the Induction and Progression of Autoimmune Diseases
Current Molecular Medicine Exploring the Phosphatidylcholine in Inflammatory Bowel Disease: Potential Mechanisms and Therapeutic Interventions
Current Pharmaceutical Design Personalized Therapies in Pediatric Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design A Review on Defects of Dendritic Cells in Common Variable Immunodeficiency
Endocrine, Metabolic & Immune Disorders - Drug Targets